Adrian Rawcliffe - Jan 11, 2022 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Signature
/s/ Adrian George Rawcliffe
Stock symbol
ADAP
Transactions as of
Jan 11, 2022
Transactions value $
-$61,877
Form type
4
Date filed
1/13/2022, 08:01 PM
Previous filing
Jan 5, 2022
Next filing
Jan 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADAP American Depositary Shares representing Ordinary Shares Sale -$51.1K -14.4K -47.34% $3.56 16K Jan 11, 2022 Direct F1, F2, F3
transaction ADAP American Depositary Shares representing Ordinary Shares Sale -$10.8K -3.05K -47.58% $3.54 3.36K Jan 12, 2022 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
F3 The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,689 ADSs and RSU-style options and other options covering an aggregate of 21,908,172 ordinary shares of the Issuer.
F4 Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F5 The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
F6 The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,689 ADSs and RSU-style options and other options covering an aggregate of 21,908,172 ordinary shares of the Issuer.